Scarica l'app Stockscreener
92.57
1.62%
1.48
Dopo l'orario di chiusura:
92.56
-0.010
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences, Inc. (NASDAQ:GILD) Position Raised by Principal Financial Group Inc. - MarketBeat
Gilead Sciences to Present at Upcoming Investor Conference - Business Wire
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold? - Yahoo Finance
Assembly Bio and Gilead collaborate to advance antiviral therapeutic programmes - Pharmaceutical Business Review
Gilead invests in Assembly Bio to advance clinical programs - The Pharma Letter
Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis - PMLiVE
Integrase Inhibitors Market Top PlayersGilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC. - openPR
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know - Yahoo Finance
Gilead plans to halt free access to an HIV drug, worrying patient advocates - STAT
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Australia
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com
(GILD)Analyzing Gilead Sciences's Short Interest - Benzinga
Gilead’s twice-yearly PrEP chosen as breakthrough of the year - Bay Area Reporter, America's highest circulation LGBT newspaper
Merck's HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies - Fierce Biotech
Gilead raises Assembly Bio stake to ~30% - MSN
Gilead recruits Terray in AI-driven drug discovery pact - OutSourcing-Pharma.com
Assembly Bio stock rises as Gilead ups stake (ASMB:NASDAQ) - Seeking Alpha
Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding - MarketWatch
Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead - MarketWatch
Xilio Therapeutics Secures $25M Investment from Gilead - TipRanks
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs - The Manila Times
Assembly Bio Secures $30.1M Gilead Investment, Advancing Ambitious Antiviral Pipeline - StockTitan
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy - Medical Dialogues
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Page 22 | GILEAD SCIENCES INC CEDEAR EACH 4 REP 1 COM USD0.001 Trade Ideas — BCBA:GILD - TradingView
Insider Sell: Andrew Dickinson Sells 8,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus.com
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer - Yahoo Finance
Gilead and Terray Therapeutics collaborate on drug discovery - BioWorld Online
Gilead and Terray enter small molecule drug development deal - World Pharmaceutical Frontiers
Gilead, Terray Therapeutics announce research collaboration - Yahoo Finance
Gilead and Terray link to develop small-molecule therapies - Yahoo Finance
Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure - Seeking Alpha
Andrew D. Dickinson Sells 8,500 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences CFO sells $781,660 in stock - Investing.com
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Gilead's New HIV Drug Aims For Global Impact By 2026 - Finimize
Gilead, Terray to collaborate on small molecule drugs (GILD:NASDAQ) - Seeking Alpha
FDA grants breakthrough status to Gilead's lung cancer drug - Investing.com
Gilead Sciences (GILD) Granted FDA Breakthrough Therapy Designation to Trodelvy - StreetInsider.com
(sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer - Business Wire
Gilead inks multi-target deal with Terray Therapeutics - The Pharma Letter
Fresh off $120M raise, AI-powered Terray is teaming up with Gilead in multi-pronged R&D pact - Fierce Biotech
Gilead Sciences, Terray Therapeutics Set AI-Powered Research Collaboration - MarketWatch
Gilead appoints Dietmar Berger as chief medical officer - PMLiVE
Gilead partners with Terray for AI-driven drug discovery - Investing.com India
AI-discovery partnership with Gilead will help Terray achieve its pipeline goals - FirstWord Pharma
Gilead Sciences (GILD) and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies - StreetInsider.com
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies - Business Wire
B. Riley Wealth Advisors Inc. Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch
New HIV prevention drug could reach poorest countries by 2025, says health official - Marketscreener.com
GILD Obtains Positive CHMP Opinion for Liver Disease Drug - Yahoo Finance
Gilead (GILD) Upgraded to Buy: Here's Why - Yahoo Finance
Gilead names Dietmar Berger CMO as it eyes R&D reset - Endpoints News
Gilead Sciences, Inc. (NASDAQ:GILD) Sees Large Increase in Short Interest - MarketBeat
Gilead Sciences' SWOT analysis: lenacapavir success fuels HIV stock growth - Investing.com India
Synovus Financial Corp Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Franklin Resources Inc. Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Analysts Set Gilead Sciences, Inc. (NASDAQ:GILD) PT at $96.43 - MarketBeat
Exome Asset Management LLC Purchases New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
Gilead Sciences appoints Dietmar Berger as Chief Medical Officer - Indian Pharma Post
Gilead hires Dietmar Berger as CMO - BioCentury
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know - Yahoo Finance
Gilead Brings In Sanofi’s Dietmar Berger To Reset Drug Development - News & Insights
EMA backs Merck’s Welireg, Bayer’s ATTR med and Gilead’s liver drug from $4.3B deal - FiercePharma
1.83%
1.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):